Skip to main content
Erschienen in: Journal of General Internal Medicine 9/2020

24.06.2020 | Original Research

Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study

verfasst von: Andrea K. Finlay, PhD, Erica Morse, MA, Matthew Stimmel, PhD, Emmeline Taylor, BS, Christine Timko, PhD, Alex H. S. Harris, PhD, David Smelson, PsyD, Mengfei Yu, MS, Jessica Blue-Howells, MSW, Ingrid A. Binswanger, MD

Erschienen in: Journal of General Internal Medicine | Ausgabe 9/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Veterans involved in the legal system are at high risk for overdose but have lower receipt of medications for opioid use disorder than other veterans.

Objective

The study aimed to understand barriers to medication access from the perspective of legally involved veterans with opioid use disorder and people who work with these veterans in the Veterans Health Administration (VHA) and the legal system.

Design

This national qualitative study interviewed veterans and stakeholders from 14 geographically diverse VHA facilities to explore perceptions of barriers to medications for opioid use disorder.

Participants

Participants included veterans with a history of opioid use disorder and legal involvement (n = 18), VHA Veterans Justice Programs Specialists (n = 15), VHA and community substance use disorder treatment providers (n = 5), and criminal justice staff (n = 12).

Approach

We conducted interviews based on the Consolidated Framework for Implementation Research. Interview transcripts were analyzed using a team-based approach.

Key Results

Four key barriers, noted by group, were identified: (1) a preference for counseling along with or instead of medications (veterans, Specialists, treatment providers, criminal justice staff); (2) concerns about veterans using medications without a prescription, selling them, or providing them to others (veterans, Specialists, treatment providers, criminal justice staff); (3) concerns about perceived stigma towards medication use (veterans, Specialists, treatment providers, criminal justice staff); and (4) concerns about medication discontinuation after recurrent opioid use (veterans, criminal justice staff). A fifth theme, education, was noted by all stakeholders except providers as important to facilitating use of medications for opioid use disorder. All five themes mapped to the framework construct of knowledge and beliefs about the intervention.

Conclusions

Based on identified barriers, interventions focused on enhancing medication knowledge, reducing stigma towards use of medications, and increasing knowledge that opioid use may recur during treatment may help increase access to medication for veterans with legal involvement.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348-54.PubMedPubMedCentral Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348-54.PubMedPubMedCentral
2.
Zurück zum Zitat Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.PubMedPubMedCentral Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.PubMedPubMedCentral
3.
Zurück zum Zitat Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018 Aug 7;169(3):137-45.PubMedPubMedCentral Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study. Ann Intern Med. 2018 Aug 7;169(3):137-45.PubMedPubMedCentral
4.
Zurück zum Zitat Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33(1):48-59.PubMedPubMedCentral Coviello DM, Cornish JW, Lynch KG, Boney TY, Clark CA, Lee JD, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33(1):48-59.PubMedPubMedCentral
5.
Zurück zum Zitat Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820-8.PubMed Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820-8.PubMed
6.
Zurück zum Zitat Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus. 2012;33(1):30-9.PubMed Gryczynski J, Kinlock TW, Kelly SM, O’Grady KE, Gordon MS, Schwartz RP. Opioid agonist maintenance for probationers: patient-level predictors of treatment retention, drug use, and crime. Subst Abus. 2012;33(1):30-9.PubMed
7.
Zurück zum Zitat Kelly SM, O’Grady K E, Jaffe JH, Gandhi D, Schwartz RP. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J Addict Med. 2013;7(2):133-8.PubMedPubMedCentral Kelly SM, O’Grady K E, Jaffe JH, Gandhi D, Schwartz RP. Improvements in outcomes in methadone patients on probation/parole regardless of counseling early in treatment. J Addict Med. 2013;7(2):133-8.PubMedPubMedCentral
8.
Zurück zum Zitat Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018 Apr;113(4):656-67.PubMed Russolillo A, Moniruzzaman A, McCandless LC, Patterson M, Somers JM. Associations between methadone maintenance treatment and crime: a 17-year longitudinal cohort study of Canadian provincial offenders. Addiction. 2018 Apr;113(4):656-67.PubMed
9.
Zurück zum Zitat Russolillo A, Moniruzzaman A, Somers JM. Association of methadone treatment with substance-related hospital admissions among a population in Canada with a history of criminal convictions. JAMA Netw Open. 2019;2(3):e190595.PubMedPubMedCentral Russolillo A, Moniruzzaman A, Somers JM. Association of methadone treatment with substance-related hospital admissions among a population in Canada with a history of criminal convictions. JAMA Netw Open. 2019;2(3):e190595.PubMedPubMedCentral
10.
Zurück zum Zitat Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396-404.PubMedPubMedCentral Evans EA, Zhu Y, Yoo C, Huang D, Hser YI. Criminal justice outcomes over 5 years after randomization to buprenorphine-naloxone or methadone treatment for opioid use disorder. Addiction. 2019;114(8):1396-404.PubMedPubMedCentral
11.
Zurück zum Zitat Larney S, Toson B, Burns L, Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction. 2012;107(2):372-80.PubMed Larney S, Toson B, Burns L, Dolan K. Effect of prison-based opioid substitution treatment and post-release retention in treatment on risk of re-incarceration. Addiction. 2012;107(2):372-80.PubMed
12.
Zurück zum Zitat Gisev N, Shanahan M, Weatherburn DJ, Mattick RP, Larney S, Burns L, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-84.PubMed Gisev N, Shanahan M, Weatherburn DJ, Mattick RP, Larney S, Burns L, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975-84.PubMed
13.
Zurück zum Zitat Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222-6.PubMedPubMedCentral Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222-6.PubMedPubMedCentral
14.
Zurück zum Zitat Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.PubMedPubMedCentral Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10(1):2.PubMedPubMedCentral
15.
Zurück zum Zitat Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev. 2017;36(3):305-10.PubMed Larney S, Zador D, Sindicich N, Dolan K. A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug Alcohol Rev. 2017;36(3):305-10.PubMed
16.
Zurück zum Zitat Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28-41.PubMedPubMedCentral Yokell MA, Zaller ND, Green TC, Rich JD. Buprenorphine and buprenorphine/naloxone diversion, misuse, and illicit use: an international review. Curr Drug Abuse Rev. 2011;4(1):28-41.PubMedPubMedCentral
17.
Zurück zum Zitat Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-6.PubMedPubMedCentral Rosenblatt RA, Andrilla CH, Catlin M, Larson EH. Geographic and specialty distribution of US physicians trained to treat opioid use disorder. Ann Fam Med. 2015;13(1):23-6.PubMedPubMedCentral
18.
Zurück zum Zitat Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374-81.PubMedPubMedCentral Oliva EM, Maisel NC, Gordon AJ, Harris AH. Barriers to use of pharmacotherapy for addiction disorders and how to overcome them. Curr Psychiatry Rep. 2011;13(5):374-81.PubMedPubMedCentral
19.
Zurück zum Zitat Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, et al. Barriers and facilitators to implementation of pharmacotherapy for opioid use disorders in VHA residential treatment programs. J Stud Alcohol Drugs. 2018;79(6):909-17.PubMedPubMedCentral Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, et al. Barriers and facilitators to implementation of pharmacotherapy for opioid use disorders in VHA residential treatment programs. J Stud Alcohol Drugs. 2018;79(6):909-17.PubMedPubMedCentral
20.
Zurück zum Zitat Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9-18.PubMedPubMedCentral Friedmann PD, Hoskinson R, Gordon M, Schwartz R, Kinlock T, Knight K, et al. Medication-assisted treatment in criminal justice agencies affiliated with the criminal justice-drug abuse treatment studies (CJ-DATS): availability, barriers, and intentions. Subst Abus. 2012;33(1):9-18.PubMedPubMedCentral
21.
Zurück zum Zitat Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473-80.PubMed Matusow H, Dickman SL, Rich JD, Fong C, Dumont DM, Hardin C, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473-80.PubMed
22.
Zurück zum Zitat Reichert J, Gleicher L. Probation clients’ barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(1):10.PubMedPubMedCentral Reichert J, Gleicher L. Probation clients’ barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(1):10.PubMedPubMedCentral
23.
Zurück zum Zitat McElrath K. Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Subst Use Misuse. 2018;53(2):334-43.PubMed McElrath K. Medication-assisted treatment for opioid addiction in the United States: Critique and commentary. Subst Use Misuse. 2018;53(2):334-43.PubMed
24.
Zurück zum Zitat Department of Veterans Affairs. Uniform Mental Health Services in VA medical centers and clinics. VHA Handbook 1160.1. Washington, DC: US Department of Veterans Affairs, Veterans Health Administration; 2008. Department of Veterans Affairs. Uniform Mental Health Services in VA medical centers and clinics. VHA Handbook 1160.1. Washington, DC: US Department of Veterans Affairs, Veterans Health Administration; 2008.
25.
Zurück zum Zitat Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U.S. Department of Veterans Affairs Veterans Justice Programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48-53. doi:https://doi.org/10.1037/a0029652CrossRefPubMed Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U.S. Department of Veterans Affairs Veterans Justice Programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48-53. doi:https://​doi.​org/​10.​1037/​a0029652CrossRefPubMed
26.
Zurück zum Zitat Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 Dec;95:43-7.PubMedPubMedCentral Finlay AK, Binswanger IA, Timko C, Smelson D, Stimmel MA, Yu M, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: Implications for implementation science. J Subst Abuse Treat. 2018 Dec;95:43-7.PubMedPubMedCentral
27.
Zurück zum Zitat Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. Manuscript submitted for publication. 2019. Finlay AK, Harris AHS, Timko C, Yu M, Smelson D, Stimmel M, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. Manuscript submitted for publication. 2019.
28.
Zurück zum Zitat Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017 Mar;27(4):591-608.PubMed Hennink MM, Kaiser BN, Marconi VC. Code saturation versus meaning saturation: how many interviews are enough? Qual Health Res. 2017 Mar;27(4):591-608.PubMed
29.
Zurück zum Zitat Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Sci. 2009;4:50. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implementation Sci. 2009;4:50.
30.
Zurück zum Zitat Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav. 2011;25(2):225-37.PubMedPubMedCentral Manuel JK, Hagedorn HJ, Finney JW. Implementing evidence-based psychosocial treatment in specialty substance use disorder care. Psychol Addict Behav. 2011;25(2):225-37.PubMedPubMedCentral
31.
Zurück zum Zitat Sorensen JL, Kosten T. Developing the tools of implementation science in substance use disorders treatment: applications of the Consolidated Framework for Implementation Research. Psychol Addict Behav. 2011;25(2):262-8.PubMedPubMedCentral Sorensen JL, Kosten T. Developing the tools of implementation science in substance use disorders treatment: applications of the Consolidated Framework for Implementation Research. Psychol Addict Behav. 2011;25(2):262-8.PubMedPubMedCentral
32.
Zurück zum Zitat Finlay AK, Ellerbe LS, Wong JJ, Timko C, Rubinsky AD, Gupta S, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat. 2017;77:38-43.PubMedPubMedCentral Finlay AK, Ellerbe LS, Wong JJ, Timko C, Rubinsky AD, Gupta S, et al. Barriers to and facilitators of pharmacotherapy for alcohol use disorder in VA residential treatment programs. J Subst Abuse Treat. 2017;77:38-43.PubMedPubMedCentral
33.
Zurück zum Zitat Atlas.ti Scientific Software Development GmbH. Atlas.ti Version 8 [Computer Software]. Berlin, Germany: Scientific Software Development; 2019. Atlas.ti Scientific Software Development GmbH. Atlas.ti Version 8 [Computer Software]. Berlin, Germany: Scientific Software Development; 2019.
34.
Zurück zum Zitat Bryant A, Charmaz K, editors. The Sage Handbook of Grounded Theory. Newbury Park, CA: Sage Publications; 2010. Bryant A, Charmaz K, editors. The Sage Handbook of Grounded Theory. Newbury Park, CA: Sage Publications; 2010.
35.
Zurück zum Zitat Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 Nov 1;180:279-85.PubMedPubMedCentral Huhn AS, Tompkins DA, Dunn KE. The relationship between treatment accessibility and preference amongst out-of-treatment individuals who engage in non-medical prescription opioid use. Drug Alcohol Depend. 2017 Nov 1;180:279-85.PubMedPubMedCentral
36.
Zurück zum Zitat Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016 Jul;66:48-53.PubMedPubMedCentral Uebelacker LA, Bailey G, Herman D, Anderson B, Stein M. Patients’ beliefs about medications are associated with stated preference for methadone, buprenorphine, naltrexone, or no medication-assisted therapy following inpatient opioid detoxification. J Subst Abuse Treat. 2016 Jul;66:48-53.PubMedPubMedCentral
37.
Zurück zum Zitat Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.PubMedPubMedCentral Winkelman TNA, Chang VW, Binswanger IA. Health, polysubstance use, and criminal justice involvement among adults with varying levels of opioid use. JAMA Netw Open. 2018;1(3):e180558.PubMedPubMedCentral
38.
Zurück zum Zitat Department of Veterans Affairs & Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. Washington, DC: Authors; 2015. Department of Veterans Affairs & Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders. Washington, DC: Authors; 2015.
39.
Zurück zum Zitat Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 (10):CD004147. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev. 2011 (10):CD004147.
40.
Zurück zum Zitat Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-67.PubMedPubMedCentral Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) national practice guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med. 2015;9(5):358-67.PubMedPubMedCentral
41.
Zurück zum Zitat Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93-103.PubMed Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. J Addict Med. 2016;10(2):93-103.PubMed
42.
Zurück zum Zitat Winograd RP, Presnall N, Stringfellow E, Wood C, Horn P, Duello A, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333-40.PubMed Winograd RP, Presnall N, Stringfellow E, Wood C, Horn P, Duello A, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333-40.PubMed
43.
Zurück zum Zitat Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2019 Jun 26. Winograd RP, Wood CA, Stringfellow EJ, Presnall N, Duello A, Horn P, et al. Implementation and evaluation of Missouri’s Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs. J Subst Abuse Treat. 2019 Jun 26.
44.
Zurück zum Zitat Montgomery AE, Hill L, Culhane DP, Kane V. Housing First implementation brief. Washington, DC: VA National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, 2014. Montgomery AE, Hill L, Culhane DP, Kane V. Housing First implementation brief. Washington, DC: VA National Center on Homelessness Among Veterans, U.S. Department of Veterans Affairs, 2014.
45.
Zurück zum Zitat Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA, Samek B, et al. Integrating a co-occurring disorders intervention in drug courts: an open pilot trial. Community Ment Health J. 2019;55(2):222-31.PubMed Smelson D, Farquhar I, Fisher W, Pressman K, Pinals DA, Samek B, et al. Integrating a co-occurring disorders intervention in drug courts: an open pilot trial. Community Ment Health J. 2019;55(2):222-31.PubMed
46.
Zurück zum Zitat Westreich LM. Use of medication-assisted treatment in the justice system: a medical perspective. Journal for Advancing Justice. 2019;2:5-19. Westreich LM. Use of medication-assisted treatment in the justice system: a medical perspective. Journal for Advancing Justice. 2019;2:5-19.
47.
Zurück zum Zitat Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.PubMed Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63-75.PubMed
48.
Zurück zum Zitat Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, et al. Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial. J Neuroimmune Pharmacol. 2018;13(4):488-97.PubMedPubMedCentral Zhu Y, Evans EA, Mooney LJ, Saxon AJ, Kelleghan A, Yoo C, et al. Correlates of long-term opioid abstinence after randomization to methadone versus buprenorphine/naloxone in a multi-site trial. J Neuroimmune Pharmacol. 2018;13(4):488-97.PubMedPubMedCentral
49.
Zurück zum Zitat Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75-80.PubMedPubMedCentral Clark RE, Baxter JD, Aweh G, O’Connell E, Fisher WH, Barton BA. Risk factors for relapse and higher costs among Medicaid members with opioid dependence or abuse: opioid agonists, comorbidities, and treatment history. J Subst Abuse Treat. 2015;57:75-80.PubMedPubMedCentral
50.
Zurück zum Zitat Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18-28.PubMedPubMedCentral Muthulingam D, Bia J, Madden LM, Farnum SO, Barry DT, Altice FL. Using nominal group technique to identify barriers, facilitators, and preferences among patients seeking treatment for opioid use disorder: A needs assessment for decision making support. J Subst Abuse Treat. 2019;100:18-28.PubMedPubMedCentral
51.
Zurück zum Zitat Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113-21.PubMed Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35(1):113-21.PubMed
52.
Zurück zum Zitat Gallagher JR, Marlowe DB, Minasian RM. Participant perspectives on medication-assisted treatment for opioid use disorders in drug court. Journal for Advancing Justice. 2019;2:39-54. Gallagher JR, Marlowe DB, Minasian RM. Participant perspectives on medication-assisted treatment for opioid use disorders in drug court. Journal for Advancing Justice. 2019;2:39-54.
53.
Zurück zum Zitat Dorman A, Badeti J, Boros A. An exploration of knowledge, opinions, and stigma regarding medication-assisted treatment among treatment and criminal justice professionals. Journal for Advancing Justice. 2019;2:93-108. Dorman A, Badeti J, Boros A. An exploration of knowledge, opinions, and stigma regarding medication-assisted treatment among treatment and criminal justice professionals. Journal for Advancing Justice. 2019;2:93-108.
54.
Zurück zum Zitat Dineen KK. Addressing prescription opioid abuse concerns in context: synchronizing policy solutions to multiple complex public health problems. Law & Psychol Rev. 2016;40:1. Dineen KK. Addressing prescription opioid abuse concerns in context: synchronizing policy solutions to multiple complex public health problems. Law & Psychol Rev. 2016;40:1.
55.
Zurück zum Zitat Johnson B, Richert T. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019;16(1):31.PubMedPubMedCentral Johnson B, Richert T. Non-prescribed use of methadone and buprenorphine prior to opioid substitution treatment: lifetime prevalence, motives, and drug sources among people with opioid dependence in five Swedish cities. Harm Reduct J. 2019;16(1):31.PubMedPubMedCentral
56.
Zurück zum Zitat Havnes IA, Clausen T, Middelthon AL. ‘Diversion’ of methadone or buprenorphine: ‘harm’ versus ‘helping’. Harm Reduct J. 2013;10:24.PubMedPubMedCentral Havnes IA, Clausen T, Middelthon AL. ‘Diversion’ of methadone or buprenorphine: ‘harm’ versus ‘helping’. Harm Reduct J. 2013;10:24.PubMedPubMedCentral
57.
Zurück zum Zitat Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of ‘generous constraints’. Int J Drug Policy. 2013;24(6):e43-50.PubMed Harris M, Rhodes T. Methadone diversion as a protective strategy: the harm reduction potential of ‘generous constraints’. Int J Drug Policy. 2013;24(6):e43-50.PubMed
58.
Zurück zum Zitat Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21-7.PubMed Larance B, Lintzeris N, Ali R, Dietze P, Mattick R, Jenkinson R, et al. The diversion and injection of a buprenorphine-naloxone soluble film formulation. Drug Alcohol Depend. 2014;136:21-7.PubMed
59.
Zurück zum Zitat Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 2014;46(5):427-35.PubMed Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 2014;46(5):427-35.PubMed
60.
Zurück zum Zitat Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.PubMedPubMedCentral Richert T, Johnson B. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden. Harm Reduct J. 2015;12:1.PubMedPubMedCentral
61.
Zurück zum Zitat Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150-7.PubMed Rubinsky AD, Chen C, Batki SL, Williams EC, Harris AH. Comparative utilization of pharmacotherapy for alcohol use disorder and other psychiatric disorders among U.S. Veterans Health Administration patients with dual diagnoses. J Psychiatr Res. 2015;69:150-7.PubMed
Metadaten
Titel
Barriers to Medications for Opioid Use Disorder Among Veterans Involved in the Legal System: a Qualitative Study
verfasst von
Andrea K. Finlay, PhD
Erica Morse, MA
Matthew Stimmel, PhD
Emmeline Taylor, BS
Christine Timko, PhD
Alex H. S. Harris, PhD
David Smelson, PsyD
Mengfei Yu, MS
Jessica Blue-Howells, MSW
Ingrid A. Binswanger, MD
Publikationsdatum
24.06.2020
Verlag
Springer International Publishing
Erschienen in
Journal of General Internal Medicine / Ausgabe 9/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-020-05944-6

Weitere Artikel der Ausgabe 9/2020

Journal of General Internal Medicine 9/2020 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.